Clinical trial: A phase I, open-label, multi-center, non-randomized, 2-part first time in human (FTIH) study for GSK2879552 has been condcuted to investigate the effect of GSK2879552 in subjects with relapsed/refractory small cell lung carcinoma. Reference:[1] Kimberly Smitheman, Monica Cus...
(LSD1, also known as KDM1A). It was under clinical investigation for the treatment of acute myeloid leukaemia and small cell lung carcinoma. It has a role as an EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor and an antineoplastic agent. It is a member of benzoic acids, ...
相关产品:Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Epigenetics Compound Library | Histone Modification Research Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Drug Repurposing ...
Introduction: This first-time-in-humans study assessed the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of GSK2879552 in patients with relapsed or refractory SCLC.Bauer, Todd M.Besse, BenjaminMartinez-Marti, AlexTrigo, Jose ManuelMoreno, VictorGarrido, PilarFerron-...
It was under clinical investigation for the treatment of acute myeloid leukaemia and small cell lung carcinoma. It has a role as an EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor and an antineoplastic agent. It is a member of benzoic acids, a monocarboxylic acid, a member ...